Integra LifeSciences Holdings Corporation IART
14.30 USD -0.47 (-3.18%)
Nov 12, 2026, 2:41 PM EST
14.27 Day range 14.93
8.70 52-week range 20.49
- YTD
- +15.14%
- 1 year
- +18.28%
News
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation (“Integra” or the “Company”) (NASDAQ: IART). Such…
seekingalpha.com Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript Integra LifeSciences Holdings Corporation (IART) Presents at 2026 UBS Global Healthcare Conference Transcript
globenewswire.com Integra LifeSciences to Present at the 2026 UBS Global Healthcare Conference PRINCETON, N.J., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holding Corporation - IART NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holding Corporation ("Integra" or the "Company") (NASDAQ: IART). Such…
benzinga.com UBS Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14 UBS analyst Patrick Wood maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $19 to $14.
benzinga.com Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $13 Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $15 to $13.
benzinga.com Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $14 Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $15 to $14.
benzinga.com BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14 BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.- benzinga.com Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $13 Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $15 to $13.
benzinga.com Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22 Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.- benzinga.com JP Morgan Maintains Underweight on Integra Lifesciences, Lowers Price Target to $14 JP Morgan analyst Robbie Marcus maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and lowers the price target from $17 to $14.
benzinga.com Integra LifeSciences' $2.1B Refinancing Merits A Closer Look Integra LifeSciences Holdings Corporation (NASDAQ:IART) completed a $2.1 billion refinancing on October 19, 2026. Its revolving credit commitment fell $700 million, from $1.3 billion to $600 million,…
benzinga.com Integra Lifesciences Q3 2026 Earnings Call Transcript Integra Lifesciences (NASDAQ:IART) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Integra Lifesciences Q3 Adj. EPS $0.59 Beats $0.56 Estimate, Sales $411.182M Miss $414.120M Estimate Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of $0.56 by 5.36 percent. This is a 9.26 percent increase over earnings of…
benzinga.com Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.30-$2.40 vs $2.42 Est; Affirms FY2026 Sales Guidance of $1.634B-$1.654B vs $1.661B Est Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.30-$2.40 to $2.30-$2.40 vs $2.42 analyst estimate. Affirms FY2026 sales outlook from $1.634 billion-$1.654 billion to $1.634…- benzinga.com Integra Lifesciences Sees Q4 Adj EPS $0.61-$0.71 vs $0.76 Est; Sees Sales $413.000M-$433.000M vs $436.772M Est Integra Lifesciences (NASDAQ:IART) is looking for Q4 Adj EPS of $0.61-$0.71 vs $0.76 analyst estimate. sees sales of $413.000 million-$433.000 million vs $436.772 million analyst estimate.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
benzinga.com Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $15 Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $19 to $15.
benzinga.com Flood Damage Prompts Integra LifeSciences To Revise 2026 Outlook Integra LifeSciences cut its 2026 financial guidance after a July flood disrupted its Cincinnati facility and negatively impacted revenue.- benzinga.com BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $15 BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $18 to $15.
benzinga.com Crude Oil Down Over 1%; US Factory Orders Edge Higher In August U.S. stocks rose Friday, led by Nasdaq (+1.27%), despite weak jobs data. Factory orders edged up; oil and gold fell. Alpha Modus surged 213%.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday's regular session. The company's market cap stands at $99.2 million. QTREX Quantum (NASDAQ:QTEX) stock…
benzinga.com Integra LifeSciences Anticipates Flooding Related Supply Disruption To Impact Q3 Revenue By ~$7M, Q4 Revenue By $15M - $20M; Expects Q3 Revenue Range Of ~$410M - $412M, Adjusted EPS Range $0.55 - $0.59; Updates FY26 Adjusted EPS Range From $2.40 - $2.50 To $2.30 - $2.40, Revenue Range From $1.654B - $1.695B To $1.634B - $1.654B Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its…- benzinga.com Integra LifeSciences Enrolls 100th Participant In Its AERA Pediatric Registry Observational Registry Integra LifeSciences (Nasdaq: IART), a leading global medical technology company, announced today the enrollment of the 100th patient in the AERA® Pediatric Registry, a prospective, multicenter…
- benzinga.com Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18 Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $15 to $18.
- benzinga.com Integra Lifesciences Sees Q3 Adj EPS $0.53-$0.61 vs $0.56 Est; Sees Sales $410.000M-$425.000M vs $418.100M Est Integra Lifesciences (NASDAQ:IART) is looking for Q3 Adj EPS of $0.53-$0.61 vs $0.56 analyst estimate. sees sales of $410.000 million-$425.000 million vs $418.100 million analyst estimate.
- benzinga.com Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.654B-$1.695B vs $1.676B Est Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654…
- benzinga.com Integra Lifesciences Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $418.761M Beat $418.647M Estimate Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 24.44 percent increase over earnings…
- benzinga.com UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19 UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.
- benzinga.com Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $19 Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $14 to $19.
- benzinga.com BMO Capital Initiates Coverage On Integra Lifesciences with Market Perform Rating, Announces Price Target of $19 BMO Capital analyst Vik Chopra initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Market Perform rating and announces Price Target of $19.
benzinga.com Citigroup Maintains Neutral on Integra Lifesciences, Raises Price Target to $19 Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and raises the price target from $16 to $19.- benzinga.com Citigroup Maintains Sell on Integra Lifesciences, Raises Price Target to $11 Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Sell and raises the price target from $9 to $11.
- benzinga.com Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $15 Wells Fargo analyst Larry Biegelsen maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $12 to $15.
benzinga.com Rockwell Automation Posts Upbeat Q2 Results, Joins EverQuote, DigitalOcean And Other Big Stocks Moving Higher On Tuesday Dow Jones up 200 points, Rockwell Automation shares rise 10.8% on strong earnings and raised guidance. Other big gainers include EverQuote, Sterling Infrastructure, and DigitalOcean.
benzinga.com Integra Lifesciences Q1 2026 Earnings Call Transcript 
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Integra Lifesciences Sees Q2 Adj EPS $0.44-$0.52 vs $0.53 Est; Sees Sales $410.000M-$425.000M vs $425.403M Est Integra Lifesciences (NASDAQ:IART) is looking for Q2 Adj EPS of $0.44-$0.52 vs $0.53 analyst estimate. sees sales of $410.000 million-$425.000 million vs $425.403 million analyst estimate.
- benzinga.com Integra Lifesciences Raises FY2026 Adj EPS Guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 Est; Affirms FY2026 Sales Guidance of $1.662B-$1.702B vs $1.674B Est Integra Lifesciences (NASDAQ:IART) raises FY2026 Adj EPS guidance from $2.30-$2.40 to $2.40-$2.50 vs $2.35 analyst estimate. Affirms FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.662…
- benzinga.com Integra Lifesciences Q1 Adj. EPS $0.54 Beats $0.41 Estimate, Sales $391.918M Beat $381.870M Estimate Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.41 by 31.71 percent. This is a 31.71 percent increase over earnings…
- benzinga.com Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $12 Truist Securities analyst Ravi Misra maintains Integra Lifesciences (NASDAQ:IART) with a Hold and lowers the price target from $13 to $12.
benzinga.com This Parsons Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Top Wall Street analysts changed outlook on top names. See all rating changes at https://www.benzinga.com/analyst-stock-ratings and analysts' views on PSN.- benzinga.com Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Lowers Price Target to $12 Wells Fargo analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and lowers the price target from $13 to $12.
- benzinga.com Earnings Scheduled For February 26, 2026
- benzinga.com Integra Lifesciences Sees Q1 Adj EPS $0.37-$0.45 vs $0.48 Est; Sees Sales $375.000M-$390.000M vs $392.147M Est Integra Lifesciences (NASDAQ:IART) is looking for Q1 Adj EPS of $0.37-$0.45 vs $0.48 analyst estimate. sees sales of $375.000 million-$390.000 million vs $392.147 million analyst estimate.
- benzinga.com Integra Lifesciences Sees FY2026 Adj EPS $2.30-$2.40 vs $2.35 Est; Sees Sales $1.662B-$1.702B vs $1.675B Est Integra Lifesciences (NASDAQ:IART) is looking for FY2026 Adj EPS of $2.30-$2.40 vs $2.35 analyst estimate. sees sales of $1.662 billion-$1.702 billion vs $1.675 billion analyst estimate.
- benzinga.com Integra Lifesciences Q4 Adj. EPS $0.83 Beats $0.80 Estimate, Sales $434.925M Beat $429.621M Estimate Integra Lifesciences (NASDAQ:IART) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.80 by 3.75 percent. This is a 14.43 percent decrease over earnings of…
benzinga.com FDA Issues Alert For Integra Wound Care Products Over Infection Fears FDA warns of high-risk device issue with wound and burn care products by Integra LifeSciences, citing infection risks.- benzinga.com FDA Says Integra Lifesciences Identified Packaging Failures Related To MediHoney Wound & Burn Products That Could Lead To A Breach In The Sterile Barrier; Integra Lifesciences Identified Production And Process Control Issues For Certain CVS Wound Gel Products; As Of December 19, 2025, Integra Lifesciences Has Reported 11 Serious Injuries Related To MediHoney Wound And Burn Products, Has Reported 3 Serious Injuries Related To CVS Wound Gel Products; Reported No Deaths Associated https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-wound-and-burn-dressing-issue-integra-lifesciences
- benzinga.com Integra LifeSciences Gets U.S. FDA's Clearance For Use Of Its CUSA Clarity Ultrasonic Surgical Aspirator System For Cardiac Surgeries Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its CUSA® Clarity Ultrasonic Surgical…